---
layout: default
title: Apremilast
parent: 僅模型預測 (L5)
nav_order: 37
evidence_level: L5
indication_count: 0
---

# Apremilast
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

The `txgnn-pipeline` skill covers pipeline operations, not report generation. I'll proceed directly with generating the evaluation report from the Evidence Pack.

---

Analyzing the Evidence Pack for APREMILAST (DB05676):

- **`predicted_indications`**: Empty array — no TxGNN predictions were produced
- **`original_indications`**: Empty — not populated in this pack
- **`original_moa`**: `[Data Gap]`
- **`taiwan_regulatory`**: Not marketed, 0 licenses
- **`safety`**: All `[Data Gap]`
- **`meta.inputs_received`**: Only `["drugbank"]` — TxGNN prediction step not completed

Given these constraints, per the output rules (no `[Data Gap]`, omit empty sections), the report below reflects only what the Evidence Pack actually contains.

---

# Apremilast: Evidence Pack Incomplete — Awaiting TxGNN Prediction Output

## One-Sentence Summary

Apremilast (DrugBank ID: DB05676) is a drug with no original indications recorded in this Evidence Pack.
The TxGNN prediction step has not been completed — **no new indications have been predicted** for this compound.
This report cannot proceed to a full repurposing evaluation until the prediction pipeline is run and evidence is collected.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in this Evidence Pack |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | Cannot be determined |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why a Full Evaluation Cannot Proceed

The Evidence Pack for Apremilast is missing three foundational inputs required for repurposing analysis:

1. **No TxGNN predictions** (`predicted_indications` is empty). The `meta.inputs_received` field shows only `"drugbank"` was ingested — the knowledge graph embedding and disease-link prediction steps have not been run for this compound.

2. **No mechanism of action data.** Without MOA, it is not possible to reason about mechanistic plausibility for any candidate indication, nor to assess whether the drug's target biology overlaps with potential new disease areas.

3. **No original indication on record.** The Evidence Pack contains an empty `original_indications` array, which prevents the standard "anchor indication → predicted indication" reasoning chain from being constructed.

Until these gaps are closed, no sections on clinical trial evidence, literature support, or mechanistic rationale can be generated.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is structurally incomplete — TxGNN has not produced any predicted indications for Apremilast, and the foundational drug-level data (original indication, MOA) required for repurposing evaluation is absent. There is no evidence base to evaluate at this stage.

**To proceed, the following is needed:**

- **Run the TxGNN prediction pipeline** for Apremilast (DB05676) against the full disease node set; populate `predicted_indications` with ranked candidates, scores, and supporting evidence
- **Retrieve MOA from DrugBank** (`DG002`, severity: High) — query DrugBank API for mechanism of action, target proteins, and pharmacological class
- **Retrieve Taiwan package insert warnings and contraindications** (`DG001`, severity: Blocking) — download and parse the TFDA package insert PDF to unblock the S1 safety screening step
- **Populate `original_indications`** — cross-reference DrugBank approved indications and any existing regulatory filings to establish the anchor indication before running the repurposing chain
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

